股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2026年1月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 清科控股有限公司* | | | 呈交日期: | 2026年2月2日 | | | I. 法定/註冊股本變動 | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01945 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | 0.0001 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 500,000,000 | USD | ...

ZERO2IPO HOLDINGS INC. 清科控股有限公司* (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） (Stock Code: 1945) (股份代號: 1945) Dear Non-registered Holder, 28 January 2026 Arrangement of Electronic Dissemination of Corporate Communications Pursuant to the amended Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") effective from 31 December 2023, Zero2IPO Holdings Inc. (the "Company") has adopted new arrangement to disseminate corporate co ...

登記股東之名稱及地址 ZERO2IPO HOLDINGS INC. 清科控股有限公司* （於開曼群島註冊成立之有限公司） (股份代號: 1945) 尊敬的股東: 2026 年 1 月 28 日 ZERO2IPO HOLDINGS INC. 清科控股有限公司* （於開曼群島註冊成立之有限公司） (股份代號: 1945) 發佈公司通訊之安排 簡介 根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）規則第 2.07A 條 1 以及清科控股有限公司* （「本公司」）的組織章程細則，本公司將以電子通訊方式向其股東 3 發佈本公司日後的公司通訊（「公司通訊 2」），並僅 應股東要求向其寄發印刷本形式的公司通訊。 為了支持通過電子郵件進行電子通訊，本公司建議股東通過掃描上述二維碼填寫線上表格，該表格的有效期為 2026 年 3 月 27 日。倘若股東因任何原因難以獲取線上表格，彼等可於日後隨時向本公司香港股份過戶登記分處（地址為香港夏慤 道 16 號遠東金融中心 17 樓）發出合理書面通知，或發送電子郵件至 1945-ecom@vistra.com 向本公司提供其電子郵箱地 址。 股東有責任提供有效的電子 ...

Core Viewpoint - The IPO market for Chinese companies showed signs of recovery in 2025, with an increase in the number of IPOs supported by VC/PE institutions and a significant rise in the value of their holdings [3][10][21]. Group 1: IPO Performance - In 2025, a total of 164 Chinese companies went public with the support of VC/PE institutions, representing a year-on-year increase of 27.1% [12]. - The total financing amount for these IPOs reached approximately RMB 170.83 billion, up 94.9% from the previous year [12]. - The average issuance return multiple for VC/PE supported IPOs rose from 3.01 in 2024 to 3.79 in 2025, indicating a recovery in return levels [11][18]. Group 2: Institutional Participation - The number of institutions benefiting from IPOs increased significantly, with 34.5% more institutions participating compared to the previous year [4]. - Five VC/PE institutions achieved over 10 IPOs in 2025, a notable increase from just one in 2024 [10]. - The top 10 institutions held a combined market value of RMB 145.72 billion in newly listed companies, a substantial increase from RMB 46.53 billion in 2024 [10]. Group 3: Sector Trends - The leading sectors for VC/PE supported IPOs shifted from semiconductors and IT in 2024 to biotechnology/healthcare, mechanical manufacturing, and semiconductors in 2025, highlighting a trend towards hard technology [11]. - Notable IPOs included companies like Moxiang Co., Moer Technology, and Xi'an Yicheng, each involving over 40 participating VC/PE institutions [11]. Group 4: Market Penetration - The VC/PE penetration rate in the Chinese IPO market was approximately 66.4% in 2025, a slight increase from the previous year [15]. - The penetration rate for A-shares was 76.7%, while the overseas market stood at 57.3%, indicating a stronger growth in the domestic market [15]. Group 5: Future Outlook - The IPO market in 2025 released positive signals, with more VC/PE institutions successfully harvesting IPO projects and a significant increase in the value of their holdings [21]. - The ongoing reforms in the A-share and Hong Kong markets are expected to continue providing important exit channels for VC/PE institutions, despite challenges in the U.S. listing environment [21].

Core Insights - The IPO market for Chinese companies is showing signs of recovery in 2025, with a total of 247 companies listed, supported by VC/PE institutions, indicating a positive trend in both domestic and international IPOs [2] VC/PE Institutions IPO Performance - In 2025, 164 Chinese companies supported by VC/PE institutions went public, involving 951 institutions, marking a 34.5% year-on-year increase in the number of institutions benefiting from IPOs [3] - The total book value of shares held by VC/PE institutions in newly listed companies reached approximately RMB 358.51 billion, a significant increase of 87.7% year-on-year [3] - Including SPAC listings, 23 VC/PE institutions held shares worth over RMB 7 billion at year-end, totaling RMB 253.42 billion [3] Total IPO Volume and Penetration Rate - The total number of VC/PE-supported IPOs rose by 27.1% in 2025, with 71 companies listed in the first half and 93 in the second half [10] - The total financing amount from VC/PE-supported IPOs was approximately RMB 170.83 billion, reflecting a 94.9% increase year-on-year [11] - The VC/PE penetration rate in the Chinese IPO market was about 66.4%, with A-shares showing a higher penetration rate of 76.7% compared to 57.3% in overseas markets [14] Average Book Return - The average book return multiple for VC/PE-supported IPOs increased to 3.79 times, reversing a downward trend since 2022 [17] - In 2025, four VC/PE institutions achieved IPO projects with returns exceeding 100 times, compared to only one in 2024 [9] Industry Trends - The distribution of VC/PE-supported IPOs shifted towards biotechnology/healthcare, mechanical manufacturing, and semiconductors, indicating a stronger focus on hard technology [10] - Notable IPOs included companies like Moxing Technology and Xian Yicai, which attracted over 40 participating VC/PE institutions, with book values around RMB 20 billion [10] Conclusion - The 2025 IPO market for Chinese companies signals a positive outlook, with increased participation from VC/PE institutions and significant growth in the book value of shares held [20] - Future strategies for VC/PE institutions should focus on enhancing research capabilities in the technology sector and fostering long-term value development in portfolio companies [20]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | | --- | | 2025年12月31日 | | 狀態: | | 新提交 | 致：香港交易及結算所有限公司 公司名稱: 清科控股有限公司* 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 備註： * 僅供識別 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01945 | 說明 | | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 299,024,400 | | 6,046,400 | | 305,070,800 | | 增加 / 減少 (-) | | | | 0 | | 0 | | ...

Core Viewpoint - The annual venture capital conference highlights the recovery and transformation in the medical investment sector, emphasizing the importance of innovation and strategic investment in the face of changing market dynamics [2][5]. Group 1: Investment Strategies and Focus Areas - Medical investment has shown significant recovery this year, with a notable increase in investment pace by approximately 50% to 60% compared to previous years [6][7]. - Key investment areas include innovative drugs, medical devices, and biomanufacturing, with a focus on projects that demonstrate true innovation capabilities [5][6][8]. - The anticipated influx of new capital, particularly from state-owned enterprises, is expected to drive early-stage project valuations higher in the coming years [7][19]. Group 2: Market Dynamics and Challenges - The medical device sector is currently undergoing a critical phase of import substitution, with many companies experiencing significant growth, particularly in overseas markets [8][9]. - Despite the recovery in the secondary market, challenges remain in the primary market, including ongoing cost control measures and the need for companies to demonstrate profitability [10][11]. - The industry is expected to face a period of consolidation, with some companies likely to exit the market as competition intensifies [8][9]. Group 3: Future Trends and Innovations - The government has prioritized biomanufacturing and related technologies as key future industries, indicating strong support for innovation in the medical sector [9][19]. - Investment in AI and brain-computer interface technologies is gaining traction, with expectations for significant advancements in these areas [26][27]. - The aging population and increasing demand for health and wellness services present substantial opportunities for growth in the medical sector [25][22]. Group 4: Long-term Perspectives and Strategic Adjustments - The focus on long-term innovation and the ability to adapt to changing market conditions are crucial for success in the medical investment landscape [17][35]. - Companies are encouraged to maintain a global perspective and invest in projects with international potential, particularly in the context of limited domestic market growth [18][19]. - Continuous learning and adaptation to new technologies and market trends are essential for sustaining competitive advantage in the medical investment field [17][35].

Core Viewpoint - The article discusses the challenges and strategies related to exit opportunities in the investment landscape, particularly focusing on private equity and venture capital exits in China, highlighting the need for adaptive strategies in a changing economic environment [2][10]. Group 1: Exit Challenges and Strategies - The current economic downturn has created significant challenges for exits, with many funds facing systemic exit difficulties, particularly for projects invested in 2014, where 70% have yet to exit [10][11]. - The exit environment has changed drastically compared to previous years, necessitating proactive management and strategic planning for exits rather than a passive approach [8][10]. - The need for organizational restructuring within investment firms has been emphasized to better manage the complexities of the current exit landscape [8][9]. Group 2: Investment Focus and Performance - Various investment firms have reported their focus areas, with East Capital managing 63 funds totaling 390 billion yuan, and Puhua Group focusing on early-stage investments in healthcare, new energy, and hard technology [3][4]. - Tianchuang Capital has successfully listed 25 portfolio companies and maintains an annual investment of 300-400 million yuan, focusing on hard technology sectors [5][6]. - The performance of exits varies, with some firms achieving notable success while others struggle, indicating a mixed landscape of exit opportunities [7][10]. Group 3: Regulatory and Market Support - Recent regulatory changes, such as the updated merger loan management measures, are expected to enhance support for mergers and acquisitions, with increased leverage ratios and more flexible financing options [12][13]. - The bond market is also seen as a potential source of lower-cost funding for mergers, with current interest rates being favorable compared to traditional loans [13]. - The overall sentiment is cautiously optimistic regarding the future of exits, with expectations of a more favorable market environment in 2026, particularly for IPOs and mergers [23][24]. Group 4: Future Outlook and Recommendations - The article suggests that investment firms should establish closer collaborations with listed companies to better align acquisition targets and exit strategies [16][17]. - There is a call for clearer investment strategies, focusing on companies with high growth potential and stable cash flows, to facilitate smoother exits [17][18]. - The importance of continuous communication with founders and portfolio companies is highlighted to ensure accurate assessments of business performance and exit timing [27][28].

Core Viewpoint - The article discusses the opportunities in embodied intelligence and AI hardware in China, highlighting the potential for companies that integrate software and hardware effectively, particularly in the fitness and robotics sectors [2]. Group 1: Company Insights - Speediance, founded in 2020, focuses on digital fitness equipment that replaces traditional weights with motors, emphasizing effective fitness guidance and meeting diverse user needs [3]. - Zhujiji Dynamics has been researching humanoid robotics since 2017, aiming to create a general-purpose robotic platform that serves households rather than factories [4]. - Speediance has benefited significantly from AI, transitioning towards an AI personal training model, capitalizing on the growing demand for fitness knowledge [4][7]. Group 2: Market Dynamics - The AI and robotics sectors in China are experiencing rapid growth, with a notable efficiency advantage in hardware iteration compared to other countries [4]. - The fitness market is seen as a certain opportunity, with a potential global market size reaching hundreds of billions, driven by health and wellness trends [10][15]. - The article suggests that the current wave of interest in humanoid robots may contain bubbles, but such bubbles are necessary for innovation and attracting talent [9][12]. Group 3: Technological Advancements - The integration of AI in health management is highlighted, with potential applications in monitoring heart rates and mental health indicators through advanced data processing [8][11]. - The discussion emphasizes the importance of data in robotics, noting that the complexity of tasks for robots requires extensive data collection and processing capabilities [13][16]. - The future of robotics is seen as reliant on the development of general-purpose robots that can meet diverse household needs, leveraging both hardware and software advancements [15].

Core Viewpoint - The rise of Corporate Venture Capital (CVC) is significantly impacting the investment landscape, focusing on industry empowerment while facing various challenges in execution and strategy [2][5][20]. Group 1: CVC Overview and Development - The annual China Private Equity Annual Conference highlights the growing influence of CVC in the investment ecosystem, with over a thousand participants from various sectors [2]. - CVCs are increasingly recognized as vital players in the investment landscape, with a focus on both financial returns and strategic industry support [5][12]. Group 2: CVC Strategies and Missions - Different CVCs have varying missions; for instance, Huasheng Fund aims for profitability while also supporting its parent company, SANY Group, in strategic transformations [6][8]. - CVCs like Shangqi Capital focus on the automotive industry, emphasizing the importance of collaboration and resource sharing within the supply chain to enhance efficiency and innovation [9][10]. Group 3: Investment Focus and Trends - Investment trends indicate a shift towards hard technology and biomedicine, with CVCs diversifying their portfolios to include emerging sectors like AI and renewable energy [4][10]. - The automotive sector is undergoing significant transformation, with CVCs adapting to the competitive landscape by investing in new technologies and startups that align with industry trends [9][10]. Group 4: Challenges and Solutions - CVCs face challenges in quantifying the value of their empowerment efforts, particularly in sectors like automotive semiconductors, where integration into existing supply chains is complex [20][21]. - The need for CVCs to develop strong internal communication and management skills is emphasized, as they must bridge the gap between innovative startups and established industry players [21][22]. Group 5: Future Directions - The future of CVCs involves a focus on long-term investment strategies, with an emphasis on patience and the ability to navigate the complexities of the manufacturing process [22][23]. - CVCs are expected to adopt more flexible investment decision-making processes to better support early-stage projects, balancing financial returns with strategic industry insights [23][24].